Compare ProShares Ultra Silver ETF (AGQ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ProShares Ultra Silver ETF vs Smith & Nephew plc — how do they compare? ProShares Ultra Silver ETF trades at $64.67, while Smith & Nephew plc trades at $30.11 (market cap $12.73B). The key difference: Smith & Nephew plc pays a 2.57% dividend while ProShares Ultra Silver ETF pays none. Which is the better fit depends on your goals.
| AGQ | SNN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $38.70 |
52-Week Low | $48.15 | $28.73 |
Market Cap | — | $12.73B |
Enterprise Value | — | $15.50B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ProShares Ultra Silver (AGQ) trades at $74.68, up 3.84% in the last session, though technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. Recent news highlights significant volatility, including a 16% intraday crash on June 7, 2026, and concerns over beta slippage eroding silver's gains. The leveraged ETF structure amplifies both gains and losses, with silver prices facing headwinds from Federal Reserve rate expectations and import restrictions.
Outlook remains cautious due to AGQ's leveraged nature and silver market volatility. Investment opportunities exist if silver rallies, but risks include Fed policy impacts, technical bearish signals, and potential delivery squeezes. Analyst sentiment is mixed, with recent downgrades highlighting downside potential over the next 3-6 months.
Smith & Nephew (SNN) trades at $30.48, up 0.76% with a bullish technical signal. The company shows improving fundamentals with revenue growing from $5.8B in 2024 to $6.2B in 2025 and net income margin expanding to 10.13%. Recent product launches in robotics and wound care demonstrate innovation momentum. Technical indicators show support at $30 and resistance at $31, with moving averages signaling bullish momentum.
SNN presents a mixed investment case with strong revenue growth and margin expansion offset by inconsistent earnings performance. The company's $500M share buyback and positive 2026 outlook provide support, but recent earnings misses and cautious analyst sentiment (68% hold rating) suggest near-term caution. Key risks include execution challenges and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
